SEC Form 4 · accession 0001140361-18-027609
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — President, Worldwide R&D
Period of report
Apr 30, 2018
Accepted (ET)
Jun 6, 2018 · 8:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 30, 2018 | A | 309 | $68.782 | A | 157,101 | D | |
| Common Stock | Jun 4, 2018 | F | 1,934 | $92.07 | D | 155,167 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares acquired by the reporting person on April 30, 2018, pursuant to the issuer's Employee Stock Purchase Plan.
- F2Amount of securities beneficially owned has been adjusted from the reporting person's prior report to: a) add 139 shares reported as acquired in the Form 4 Amendment filed with the S.E.C. on 4/26/2018; and b) subtract 23 shares reported as disposed of in the Form 4 Amendment filed with the S.E.C. on 4/27/2018.